Back to top
more

Phibro Animal Health (PAHC)

(Real Time Quote from BATS)

$26.65 USD

26.65
4,760

+0.16 (0.60%)

Updated Aug 7, 2025 10:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down

by Zacks Equity Research

Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.

Zacks Equity Research

Phibro (PAHC) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus (EOLS) delivered earnings and revenue surprises of -85.71% and 0.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Unlocking Q3 Potential of Phibro (PAHC): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Phibro (PAHC) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Should Value Investors Buy Owens & Minor (OMI) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Phibro (PAHC) Moves 31.8% Higher: Will This Strength Last?

by Zacks Equity Research

Phibro (PAHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Abbott (ABT) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 2.08% and 1.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.

Zacks Equity Research

Here's Why Investors Should Buy Phibro (PAHC) Stock Now

by Zacks Equity Research

Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.

Zacks Equity Research

Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Why Is Phibro (PAHC) Up 12.7% Since Last Earnings Report?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales

by Zacks Equity Research

Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.

Zacks Equity Research

Is Phibro Animal Health (PAHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Owens & Minor, Inc. (OMI) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Owens & Minor (OMI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

What Makes Phibro (PAHC) a New Buy Stock

by Zacks Equity Research

Phibro (PAHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down

by Zacks Equity Research

Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.

Zacks Equity Research

Phibro (PAHC) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Phibro Animal Health (PAHC) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Phibro (PAHC) delivered earnings and revenue surprises of 22.22% and 2.88%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stocks' Earnings Due on Feb 7: STE, PAHC & NVST

by Urmimala Biswas

Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how STE, PAHC and NVST fare this time.

Zacks Equity Research

Why Is Phibro (PAHC) Up 13.6% Since Last Earnings Report?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down

by Zacks Equity Research

Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.

Zacks Equity Research

Phibro (PAHC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.